PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
Open Access
- 19 August 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (32), 33019-33032
- https://doi.org/10.18632/oncotarget.5028
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Wenfeng Fang1, 2, *, Shaodong Hong1, 2, *, Nan Chen3, *, Xiaobo He3, Jianhua Zhan1, 2, Tao Qin1, 2, Ting Zhou1, 2, Zhihuang Hu1, 2, Yuxiang Ma1, 2, Yuanyuan Zhao1, 2, Ying Tian1, 2, Yunpeng Yang1, 2, Cong Xue1, 2, Yanna Tang3, Yan Huang1, 2, Hongyun Zhao1, 2, Li Zhang1, 2 1State Key laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China 2Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China 3Department of Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China *These authors have contributed equally to this work Correspondence to: Li Zhang, e-mail: zhangli@sysucc.org.cn Keywords: pulmonary lymphoepithelioma-like carcinoma, PD-L1, Epstein–Barr virus Received: May 07, 2015 Accepted: August 14, 2015 Published: August 24, 2015 ABSTRACT Backgroud: Programmed cell death-ligand 1 (PD-L1) and driver mutations are commonly seen in non-small-cell lung cancer (NSCLC). However, the prevelance of PD-L1 over-expression and its prognostic value in Epstein–Barr virus (EBV) associated pulmonary lymphoepithelioma-like carcinoma (LELC) remains poorly understood. Methods: A total of 214 NSCLC patients and 113 surgically treated pulmonary LELC patients were included. Paraffin-embedded tumor sections were stained with PD-L1 antibody. Correlations between PD-L1 expression and clinicopathological features as well as survival outcomes were analyzed. Results: The frequency of PD-L1 over-expression in NSCLC was 51.4%. No significant association was observed between common driver mutations and PD-L1 over-expression. Remakably, the positive rate of PD-L1 in pulmonary LELC was 74.3%. High PD-L1 expression was associated with impaired diseas-free survival (DFS) compared with low PD-L1 expression (p = 0.008). Multivariate analysis shows that PD-L1 expression level, N stage and M stage were independent prognostic factors for DFS. N stage and M stage but not PD-L1 expression level were significantly associated with overall survival (OS). Conclusions: PD-L1 over-expression was not related to common driver mutations in NSCLC. Pulmonary LELC have remarkably high incidence of PD-L1 expression. PD-L1 was a negative prognostic factor for DFS in surgically resected pulmonary LELC. These findings may provide a rationale for immunotarget therapy in this virus-associated lung cancer.Keywords
This publication has 33 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Primary pulmonary lymphoepithelioma‐like carcinomaCancer, 2012
- Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinomaWorld Journal of Gastroenterology, 2011
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- X-TileClinical Cancer Research, 2004
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- Association of Epstein-Barr Virus With Lymphoepithelioma-Like Carcinoma of the Lung in Southern ChinaAmerican Journal of Clinical Pathology, 2000
- Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lungJournal of Surgical Oncology, 1987